These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 32584876)
41. Acute kidney injury due to sucrose-containing intravenous immunoglobulins. Siddiqui W; Al Lawati S; Shaheen Faissal AM; Hannawi S; Al Riyami M; Al Salmi I Saudi J Kidney Dis Transpl; 2019; 30(3):732-737. PubMed ID: 31249243 [TBL] [Abstract][Full Text] [Related]
42. Inconsistent excipient listings in DailyMed: implications for drug safety. Kinsella L; Brook J; Briest M; Brook MJ Naunyn Schmiedebergs Arch Pharmacol; 2024 Sep; 397(9):6851-6854. PubMed ID: 38563879 [TBL] [Abstract][Full Text] [Related]
43. A new approach to the safety assessment of pharmaceutical excipients. The Safety Committee of the International Pharmaceutical Excipients Council. Steinberg M; Borzelleca JF; Enters EK; Kinoshita FK; Loper A; Mitchell DB; Tamulinas CB; Weiner ML Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 1):149-54. PubMed ID: 8933628 [TBL] [Abstract][Full Text] [Related]
44. Biopharmaceutical aspects and implications of excipient variability in drug product performance. Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182 [TBL] [Abstract][Full Text] [Related]
45. Classification of lyophilised mixtures using multivariate analysis of NIR spectra. Grohganz H; Fonteyne M; Skibsted E; Falck T; Palmqvist B; Rantanen J Eur J Pharm Biopharm; 2010 Feb; 74(2):406-12. PubMed ID: 19577644 [TBL] [Abstract][Full Text] [Related]
46. What are excipients doing in medicinal products? Drug Ther Bull; 2009 Jul; 47(7):81-4. PubMed ID: 19567843 [TBL] [Abstract][Full Text] [Related]
47. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing. Bejarano A; Hewa Nadungodage C; Wang F; Catlin AC; Hoag SW AAPS PharmSciTech; 2019 Jun; 20(6):223. PubMed ID: 31214878 [TBL] [Abstract][Full Text] [Related]
48. Harmful excipients in medicines for neonates in Spain. Garcia-Palop B; Movilla Polanco E; Cañete Ramirez C; Cabañas Poy MJ Int J Clin Pharm; 2016 Apr; 38(2):238-42. PubMed ID: 26960405 [TBL] [Abstract][Full Text] [Related]
49. In vitro hemolysis: guidance for the pharmaceutical scientist. Amin K; Dannenfelser RM J Pharm Sci; 2006 Jun; 95(6):1173-6. PubMed ID: 16639718 [TBL] [Abstract][Full Text] [Related]
50. Potential aspects of chitosan as pharmaceutical excipient. Ray SD Acta Pol Pharm; 2011; 68(5):619-22. PubMed ID: 21928704 [TBL] [Abstract][Full Text] [Related]
51. Safety verification for polysorbate 20, pharmaceutical excipient for intramuscular administration, in Sprague-Dawley rats and New Zealand White rabbits. Kim J; Kwak S; Park MS; Rhee CH; Yang GH; Lee J; Son WC; Kang WH PLoS One; 2021; 16(8):e0256869. PubMed ID: 34449810 [TBL] [Abstract][Full Text] [Related]
52. The safety of pharmaceutical excipients. Pifferi G; Restani P Farmaco; 2003 Aug; 58(8):541-50. PubMed ID: 12875883 [TBL] [Abstract][Full Text] [Related]
54. Excipient variability and its impact on dosage form functionality. Dave VS; Saoji SD; Raut NA; Haware RV J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249 [TBL] [Abstract][Full Text] [Related]
55. The influence of water on the stability of lyophilized formulations with inositol and mannitol as excipients. Terakita A; Matsunaga H; Handa T Chem Pharm Bull (Tokyo); 2009 May; 57(5):459-63. PubMed ID: 19420775 [TBL] [Abstract][Full Text] [Related]
56. A Narrative Literature Review of the Established Safety of Human Serum Albumin Use as a Stabilizer in Aesthetic Botulinum Toxin Formulations Compared to Alternatives. Sattler S; Gollomp S; Curry A Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888650 [TBL] [Abstract][Full Text] [Related]
57. Effect of cations and anions on glass transition temperatures in excipient solutions. Nesarikar VV; Nassar MN Pharm Dev Technol; 2007; 12(3):259-64. PubMed ID: 17613889 [TBL] [Abstract][Full Text] [Related]